Early access
Sign in
Taking people in United StatesNo phase

Treatment Results for Recurrent Retroperitoneal Liposarcoma That Can Be Removed by Surgery

Follows treatment results in adults whose retroperitoneal liposarcoma has come back once.

Key facts

Who runs it
Australia and New Zealand Sarcoma Association
Where
Atlanta, Boston, Columbus, and Houston, United StatesSee the 4 sitesAlso in 7 other countries, 9 sites
Trial code
Registry title
Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
Status
Recruiting
People taking part
100 people, planned
Started
5 Sept 2024
Expected to end
Dec 2032
Type of study
Observational, 2 groups
Record updated
15 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose well-differentiated or dedifferentiated retroperitoneal liposarcoma has come back for the first time, has not spread to distant organs, and can be removed by surgery.

Age
18 years or older
Sex
All sexes can join.
Disease stage
First recurrence of well-differentiated and/or dedifferentiated liposarcoma in the retroperitoneal space or pelvis, after earlier surgery that removed all visible tumour. No distant metastasis. The tumour must be resectable, and all disease must be treatable by radiotherapy (RT). WHO performance status 0-2 and ASA score 1-3.
Earlier treatment
No earlier radiotherapy for the retroperitoneal liposarcoma. Earlier drug treatment (systemic therapy) is allowed. Earlier surgery with complete removal (R0/R1 resection) is required.

Main reasons for not taking part

  • Disease that cannot be removed by surgery, or likely R2 resection
  • Recurrence too extensive for radiotherapy to all visible disease
  • Reasons against radiotherapy, such as past bowel obstruction, mesenteric ischemia or severe chronic inflammatory bowel disease
  • Myxoid liposarcoma
  • Pregnancy

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Adult age ≥ 18 presenting with first recurrent well-differentiated and/or dedifferentiated liposarcoma of retroperitoneal space or pelvis after previous macroscopically complete resection (R0/R1 resection)
  • No distant metastasis on cross-sectional imaging of chest/abdomen/pelvis (CT and/or MRI) within 1 month to confirm the absence of metastatic disease
  • Previous histologically proven well-differentiated or dedifferentiated liposarcoma histology only
  • Sarcoma not originating from bone or abdominal or gynecological viscera
  • Tumor confirmed to be resectable with likely R0/R1 resection, and all disease must be deemed to be treatable by RT (joint decision by surgeon and radiation oncologist at a sarcoma multidisciplinary team meeting)
  • WHO performance status 0-2
  • American Society of Anaesthesiologist (ASA) score 1-3
  • No prior RT for the retroperitoneal liposarcoma
  • Prior systemic therapy is allowed
  • No concurrent active malignancy (except for low risk skin malignancy, low risk prostate carcinoma, low risk breast carcinoma including in situ disease)
  • Women of childbearing potential must have a negative pregnancy test within 3 weeks prior to the first day of study treatment
  • Patient deemed able to comply with study requirements according to investigator evaluation
  • Signed, IRB-approved written informed consent

Who cannot take part

  • Unresectable disease or likely R2 resection as assessed by the multidisciplinary sarcoma team
  • Extent of recurrence where preoperative RT to all visible disease is not deemed to be feasible
  • Contradiction for RT such as history of bowel obstruction or mesenteric ischemia or severe chronic inflammatory bowel disease
  • Myxoid liposarcoma histology
  • Pregnancy

Where in United States

Also in 7 other countries, 9 sites

  • Emory Winship Cancer InstituteAtlanta, United StatesContact: Jennifer GlassTaking people
  • Brigham and Women's HospitalBoston, United StatesContact: Kodey SilknitterNot yet recruiting
  • OSU James HospitalColumbus, United StatesContact: David KonieczkowskiTaking people
  • MD Anderson Cancer CenterHouston, United StatesContact: Amalia GonzalezTaking people

About the trial

What the trial wants to find out

The aim of the study is to collect prospective data on the treatment outcomes in patients with first localized, resectable recurrent retroperitoneal well-differentiated and/or dedifferentiated liposarcoma undergoing curative intent treatment. Patients enrolled in this study will form a validation cohort of the TARPSWG recurrent RPS nomogram. The treatment decision (surgery alone, or preoperative RT +/- chemotherapy followed by surgery) is per the institutional multidisciplinary team recommendation.

The 2 groups in the trial

  • Surgery with preoperative radiotherapy

    This includes patient who have had any chemotherapy.

  • Surgery without preoperative radiotherapy

    This includes patients who had surgery alone, surgery with postoperative radiotherapy and/or any chemotherapy.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
Plain-language title
Treatment Results for Recurrent Retroperitoneal Liposarcoma That Can Be Removed by SurgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
15 July 2026